Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 3:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 126 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: injected insulin Clear all
Completed Phase 3 Interventional Results available

A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus

NCT02501161
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/liraglutide, insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,012 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
44
States / cities
Muscle Shoals, Alabama • Tuscumbia, Alabama • Glendale, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Sep 30, 2026, 3:25 PM EDT
Terminated Phase 4 Interventional Results available

The LANCET Trial: A Trial of Long-acting Insulin Injection to Reduce C-reactive Protein in Patients With Type 2 Diabetes

NCT00366301
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Insulin glargine injection, metformin, Placebo pill
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 79 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 25, 2010 · Synced Sep 30, 2026, 3:25 PM EDT
Completed Not applicable Interventional Results available

PRP vs PRP Plus IGF for Patellar Tendinosis

NCT04350827
View directory record Official record
Conditions
Tendinopathy, Patellar Ligament, Platelet-Rich Plasma
Interventions
Platelet Rich Plasma, Platelet Rich Plasma plus IGF
Device
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Sep 30, 2026, 3:25 PM EDT
Completed Phase 1 Interventional

The Effect of NN1250 in Subjects With Type 2 Diabetes of Different Race and/or Ethnic Origin

NCT01043510
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec, insulin detemir
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 70 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Sep 30, 2026, 3:25 PM EDT
Completed Phase 3 Interventional Results available

A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus

NCT01513473
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
insulin degludec, insulin detemir, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
1 Year to 17 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
28
States / cities
Little Rock, Arkansas • Orange, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Sep 30, 2026, 3:25 PM EDT
Completed Phase 4 Interventional Results available

The Effect of Insulin Glulisine Compared With Insulin Aspart on Breakfast Post Prandial Glucose Levels in Prepubertal Children

NCT00913497
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
insulin glulisine, insulin aspart
Drug
Lead sponsor
Corewell Health West
Other
Eligibility
4 Years to 11 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Sep 30, 2026, 3:25 PM EDT
Completed Phase 3 Interventional Results available

Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes

NCT01076647
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec, insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
66
States / cities
Birmingham, Alabama • Peoria, Arizona • Tucson, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Sep 30, 2026, 3:25 PM EDT
Completed Phase 4 Interventional Results available

Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes

NCT01232491
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
Insulin detemir, Dietary regimen
Drug · Dietary Supplement
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
611 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
76
States / cities
Birmingham, Alabama • Ozark, Alabama • Anaheim, California + 63 more
Source: ClinicalTrials.gov public record
Updated May 1, 2017 · Synced Sep 30, 2026, 3:25 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes

NCT02128932
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
semaglutide, insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,089 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
136
States / cities
Birmingham, Alabama • Ozark, Alabama • Tuscumbia, Alabama + 117 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Sep 30, 2026, 3:25 PM EDT
Completed Phase 4 Interventional Results available

Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease

NCT01006889
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus
Interventions
Exenatide
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2016 · Synced Sep 30, 2026, 3:25 PM EDT
Completed Not applicable Interventional Results available

IV Insulin Protocol in Diabetes and Renal Transplantation

NCT00609986
View directory record Official record
Conditions
Kidney Transplantation, Diabetes, Hyperglycemia
Interventions
insulin, NPH Insulin or glargine insulin and aspartame insulin
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 6, 2013 · Synced Sep 30, 2026, 3:25 PM EDT
Completed Phase 2 Interventional

Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes

NCT00434850
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Allogeneic Pancreatic Islet Cells, Deoxyspergualin, Antithymocyte globulin, Daclizumab or basiliximab, Sirolimus, Tacrolimus, Etanercept
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
3
States / cities
San Francisco, California • Chicago, Illinois • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Sep 30, 2026, 3:25 PM EDT
Completed Phase 3 Interventional Results available

The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)

NCT00069784
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
insulin glargine (HOE901), omega-3 polyunsaturated fatty acids (PUFA), placebo, reusable pen device for insulin injection
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older
Enrollment
12,537 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Sep 30, 2026, 3:25 PM EDT
Terminated Phase 3 Interventional

Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics

NCT01308437
View directory record Official record
Conditions
Type I Diabetes
Interventions
Wosulin (N or 70/30 with R), Novolin® (N or 70/30 with R)
Biological
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years to 55 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
17
States / cities
Tustin, California • Hialeah, Florida • Hollywood, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2023 · Synced Sep 30, 2026, 3:25 PM EDT
Completed Phase 2 Interventional Results available

Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus

NCT01194245
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Insulin lispro, recombinant human hyaluronidase PH20, Insulin aspart, Insulin glulisine, Insulin glargine
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
19
States / cities
Escondido, California • La Jolla, California • San Mateo, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Sep 30, 2026, 3:25 PM EDT
Completed Early Phase 1 Interventional

Acceleration of Insulin Action by Hyaluronidase During Closed-Loop Therapy

NCT01945099
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
ePID closed loop system, hyaluronidase, Lispro-PH20
Device · Drug
Lead sponsor
Yale University
Other
Eligibility
12 Years to 40 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Sep 30, 2026, 3:25 PM EDT
Completed Phase 3 Interventional Results available

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus

NCT01683266
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
HOE901-U300 (Insulin glargine new formulation), Lantus (Insulin glargine)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
82
States / cities
Chandler, Arizona • Little Rock, Arkansas • Bell Gardens, California + 71 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2015 · Synced Sep 30, 2026, 3:25 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Two Basal Insulins for Patients With Type 2 Diabetes on Anti-Hyperglycemic Medications (IOPE)

NCT00510952
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin Lispro Protamine Suspension, Insulin Glargine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
11
States / cities
Jonesboro, Arkansas • Huntington Park, California • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2010 · Synced Sep 30, 2026, 3:25 PM EDT
Completed Phase 2 Interventional Results available

Feasibility Study of Finesse for Bolus Prandial Insulin Dosing Compared to Multiple Daily Injections

NCT01073566
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Finesse, Pen/Syringe (Usual injection device)
Device
Lead sponsor
Calibra Medical, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
5
States / cities
San Francisco, California • Chicago, Illinois • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Sep 30, 2026, 3:25 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Insulin Degludec/Insulin Aspart in Insulin-naïve Subjects With Type 2 Diabetes Using Two Dosing Regimens

NCT01365507
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
25
States / cities
Concord, California • Los Angeles, California • Montclair, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2017 · Synced Sep 30, 2026, 3:25 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Pharmacogenetics of Response to GLP1R Agonists

NCT05071898
View directory record Official record
Conditions
Obesity, Diabetes Type 2
Interventions
Semaglutide Pen Injector [Ozempic]
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 89 Years
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 30, 2026, 3:25 PM EDT
Active, not recruiting No phase listed Observational

T1D Pregnancy & Me

NCT06959316
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Pregnancy in Diabetics, Pregnancy, High-Risk, Insulin Dependent Diabetes
Interventions
Hybrid closed loop insulin delivery system
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older · Female only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
10
States / cities
Birmingham, Alabama • Aurora, Colorado • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 30, 2026, 3:25 PM EDT
Completed Phase 3 Interventional Results available

Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine

NCT03211858
View directory record Official record
Conditions
Type 1 Diabetes Mellitus-Type 2 Diabetes Mellitus
Interventions
Insulin aspart, NovoLog/NovoRapid, Insulin glargine (HOE901)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
597 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
42
States / cities
Little Rock, Arkansas • Concord, California • Escondido, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Sep 30, 2026, 3:25 PM EDT
Not listed Phase 1 Interventional

PK/PD Study of Intranasal Insulin in Type I Diabetes

NCT01201278
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Insulin, Insulin LISPRO
Drug
Lead sponsor
Hompesch, Marcus, M.D.
Individual
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jun 17, 2011 · Synced Sep 30, 2026, 3:25 PM EDT